AlgiPharma AS

AlgiPharma is attending the 17th Global Drug Delivery & Formulation (DDF) Summit 2026 in Berlin from May 18–20, 2026. This event is a valuable opportunity for AlgiPharma to meet industry experts to discuss advancements in drug delivery, and formulation. We are looking forward to using the opportunity to further our drug delivery program through discussions with new companies and catching up with existing partners. Attendees from AlgiPharma will be our CEO, Yngvar Berg, CMO, Dr. Yngve Mikkelsen. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for: Delivery platforms for nanoparticles, small and large molecule based drugs. Drug conjugates, adding functionality and reducing toxicity of parent compound. API in disease areas such as cystic fibrosis, COPD, and infectious diseases. AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents. AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA. AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF). AlgiPharma is a privately owned company registered and domiciled in Norway. For additional information contact: Yngvar P. Berg, CEO: yngvar.berg@algipharma.com Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

Alginate-Amphotericin B bifunctional conjugates have improved solubility and reduced toxicity We’re very pleased to announce a new publication of AlgiPharma’s technology that highlights the potential to improve drug delivery through conjugation chemistry with AlgiPharma’s low molecular weight alginate oligosaccharides, creating novel bifunctional antimicrobial compounds. The work was carried out in collaboration with first-class research teams at NTNU and SINTEF, Trondheim, Norway. You can access the article on PubMed here: https://pubmed.ncbi.nlm.nih.gov/41832013/ About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for: Delivery platforms for nanoparticles, small and large molecule based drugs. Drug conjugates, adding functionality and reducing toxicity of parent compound. API in disease areas such as cystic fibrosis, COPD, and infectious diseases. AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents. AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA. AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF). AlgiPharma is a privately owned company registered and domiciled in Norway. For additional information contact: Yngvar P. Berg, CEO: yngvar.berg@algipharma.com Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma attended and presented at this year’s Partnership Opportunities in Drug Delivery (PODD) conference in Boston. Dr. Yngve Mikkelsen (CMO) had the opportunity to present AlgiPharma’s work on alginate oligosaccharides as a next-generation delivery platform for GLP-1 receptor agonists and beyond. Our data demonstrate how AlgiPharma’s technology enhances oral bioavailability and improves mucus translocation for biologics and lipid nanoparticles, opening new frontiers in drug delivery and therapeutic design. A huge thank you to the organizers for another excellent and engaging event. It was great to reconnect with familiar faces and meet new collaborators across the biotech and pharma landscape and the energy around innovation in drug delivery is inspiring. Attendees from AlgiPharma: CEO, Yngvar Berg, CMO, Yngve Mikkelsen, and CSO, Dr. Philip Rye. If you couldn’t attend but would like to learn more about our work, don’t hesitate to reach out or visit www.algipharma.com About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for: Delivery platforms for nanoparticles, small and large molecule based drugs. Drug conjugates, adding functionality and reducing toxicity of parent compound. API in disease areas such as cystic fibrosis, COPD, and infectious diseases. AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents. AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA. AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF). AlgiPharma is a privately owned company registered and domiciled in Norway. For additional information contact: Yngvar P. Berg, CEO: yngvar.berg@algipharma.com Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com